{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T11:59:32Z","timestamp":1774353572708,"version":"3.50.1"},"reference-count":19,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T00:00:00Z","timestamp":1727308800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>The platelet human leucocyte antigen (HLA) gene bank contains the genetic information of HLA loci in a large number of blood donors. Currently, the most effective treatment for platelet transfusion refractoriness (PTR) is to evaluate the probability of antigenic mismatch by HLA genotyping of patients and to select HLA-matched donors in the gene bank through an information system. This case report describes the treatment of PTR in patients with malignant tumors using the platelet HLA gene bank digital matching technique. The analysis of individual cases will help guide transfusion strategies for such patients.<\/jats:p>","DOI":"10.3389\/fonc.2024.1419485","type":"journal-article","created":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T05:10:25Z","timestamp":1727327425000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Platelet HLA gene bank digital matching technology for platelet transfusion refractory patients with malignant tumors: a case report"],"prefix":"10.3389","volume":"14","author":[{"given":"Xiang","family":"Gao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianhua","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiuwen","family":"Ni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lijun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peilin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaowei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,9,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07189.x","article-title":"Platelet transfusion refractoriness","volume":"142","author":"Hod","year":"2008","journal-title":"Br J Haematol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2020000137","article-title":"Platelet transfusion refractoriness: how do I diagnose and manage","volume":"2020","author":"Cohn","year":"2020","journal-title":"Hematol 2014 Am Soc Hematol Educ Program Book"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.983644","article-title":"Related donor platelet transfusion improves platelet transfusion refractoriness in hematological patients","volume":"10","author":"Zhang","year":"2023","journal-title":"Front Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1111\/trf.16134","article-title":"Evaluating the appropriateness of platelet transfusions compared with evidence-based platelet guidelines: An audit of platelet transfusions at 57 hospitals","volume":"61","author":"Hill-Strathy","year":"2021","journal-title":"Transfusion"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmrv.2020.09.002","article-title":"Non-alloimmune mechanisms of thrombocytopenia and refractoriness to platelet transfusion","volume":"34","author":"Belizaire","year":"2020","journal-title":"Transfus Med Rev"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1080\/09537104.2024.2306983","article-title":"Immunological platelet transfusion refractoriness: current insights from mechanisms to therapeutics","volume":"35","author":"Chen","year":"2024","journal-title":"Platelets"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1998.tb01007.x","article-title":"Successful treatment of platelet transfusion refractoriness: the use of platelet transfusions matched for both human leucocyte antigens (HLA) and human platelet alloantigens (HPA) in alloimmunized patients with leukaemia","volume":"60","author":"Kekom\u00e4ki","year":"1998","journal-title":"Eur J Haematol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.cca.2019.08.009","article-title":"A single-center investigational study of CD36 antigen deficiency and platelet alloantibody distribution in different populations in Northern China as well as platelet alloantibodies effect on pregnancy","volume":"498","author":"Ma","year":"2019","journal-title":"Clinica Chimica Acta"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/trf.14316","article-title":"How do I \u2026 manage the platelet transfusion\u2013refractory patient","volume":"57","author":"Juskewitch","year":"2017","journal-title":"Transfusion"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/trf.16358","article-title":"Platelet transfusion refractoriness and anti-HLA immunization","volume":"61","author":"Blandin","year":"2021","journal-title":"Transfusion"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/trf.15108","article-title":"HLA-selected platelets for platelet refractory patients with HLA antibodies: a single-center experience","volume":"59","author":"Karlstr\u00f6m","year":"2019","journal-title":"Transfusion"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2021.01.002","article-title":"Incidence and impact of allele-specific anti-HLA antibodies and high-resolution HLA genotyping on assessing immunologic compatibility","volume":"82","author":"Zavyalova","year":"2021","journal-title":"Hum Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.530478","article-title":"Immune thrombocytopenia induced by immune checkpoint inhibitors in solid cancer: case report and literature review","volume":"10","author":"Liu","year":"2020","journal-title":"Front Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"102657","DOI":"10.1016\/j.transci.2019.09.010","article-title":"Efficacy of cross-match compatible platelets in multi transfused haemato-oncology patients refractory to platelet transfusion","volume":"58","author":"Chavan","year":"2019","journal-title":"Transfus Apheresis Sci"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2022.103622","article-title":"Comparison of platelet antibody screen, crossmatching and HLA antibody testing in patients refractory to platelet transfusions","volume":"62","author":"Chapman","year":"2023","journal-title":"Transfus Apheresis Sci"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/trf.15728","article-title":"Ensuring HLA-matched platelet support requires an ethnic diverse donor population","volume":"60","author":"Kreuger","year":"2020","journal-title":"Transfusion"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/trf.15664","article-title":"Efficacy of HLA virtual cross-matched platelet transfusions for platelet transfusion refractoriness in hematopoietic stem cell transplantation","volume":"60","author":"Seike","year":"2020","journal-title":"Transfusion"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/trf.16025","article-title":"Development and performance characteristics of Platelet Virtual Crossmatch (PLT VXM), a software application for the evaluation and management of platelet transfusion\u2013refractory patients","volume":"60","author":"Juskewitch","year":"2020","journal-title":"Transfusion"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s12288-022-01547-9","article-title":"Methodological study on the establishment of HLA\/HPA gene bank of platelet donors and its clinical application","volume":"39","author":"Xu","year":"2023","journal-title":"Indian J Hematol Blood Transfus"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1419485\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T05:10:27Z","timestamp":1727327427000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1419485\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,26]]},"references-count":19,"alternative-id":["10.3389\/fonc.2024.1419485"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2024.1419485","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,26]]},"article-number":"1419485"}}